Inhibition of platelet aggregation (Update 2023)

被引:0
|
作者
Wascher, Thomas C. M. [1 ]
Stulnig, Thomas M. H. [2 ,3 ]
Saely, Christoph H. [4 ,5 ]
Stechemesser, Lars [6 ]
机构
[1] Hanuschkrankenhaus, Med Abt 1, Vienna, Austria
[2] Klin Hietzing, Med Abt 3, Vienna, Austria
[3] Klin Hietzing, Karl Landsteiner Inst Stoffwechselerkrankungen & N, Vienna, Austria
[4] VIVIT Inst, Abt Innere Med 1, Akadem Lehrkrankenhaus Feldkirch, Feldkirch, Austria
[5] Private Univ Furstentum Liechtenstein, Triesen, Liechtenstein
[6] Paracelsus Med Privatuniv, Univ Klin Innere Med 1, Mullner Hauptstr 48, A-5020 Salzburg, Austria
关键词
Platelets anti platelet drugs; Acute atherothrombosis; Diabetes mellitus; COLLABORATIVE METAANALYSIS; PRIMARY PREVENTION; ASPIRIN; EVENTS;
D O I
10.1007/s00508-023-02168-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute thrombotic complications as a key feature of accelerated atherothrombotic disease typically precipitate cardiovascular events and therefore strongly contribute to cardiovascular morbidity and mortality in patients with diabetes. Inhibition of platelet aggregation can reduce the risk for acute atherothrombosis. The present article represents the recommendations of the Austrian Diabetes Association for the use of antiplatelet drugs in patients with diabetes according to current scientific evidence.
引用
收藏
页码:161 / 163
页数:3
相关论文
共 50 条